NEULANDLAB.NS Balance Sheet
Neuland Laboratories Ltd.
Profit & Loss Balance Sheet Cash Flow
Balance Sheet · 4 years on file
(FY2022-23 to FY2025-26)
· fetched 2026-08-23 23:40
| Line item | FY2022-23 | FY2023-24 | FY2024-25 | FY2025-26 | Source (XBRL element) |
|---|---|---|---|---|---|
| Property, Plant and Equipment | ₹4.57 Bn | ₹5.23 Bn | ₹6.74 Bn | ₹8.92 Bn | PropertyPlantAndEquipment |
| Capital Work-in-Progress | ₹0.41 Bn | ₹0.46 Bn | ₹0.45 Bn | ₹2.09 Bn | CapitalWorkInProgress |
| Goodwill | ₹2.79 Bn | ₹2.79 Bn | ₹2.79 Bn | ₹2.79 Bn | Goodwill |
| Other Intangible Assets | ₹0.01 Bn | ₹0.02 Bn | ₹0.02 Bn | ₹0.05 Bn | OtherIntangibleAssets |
| Non-current Investments | ₹0.01 Bn | ₹0.01 Bn | ₹0.02 Bn | ₹0.02 Bn | NoncurrentInvestments |
| Other Non-current Assets | ₹0.13 Bn | ₹0.32 Bn | ₹0.16 Bn | ₹0.46 Bn | OtherNoncurrentAssets |
| Total Non-current Assets | ₹8.19 Bn | ₹9.11 Bn | ₹10.40 Bn | ₹14.47 Bn | NoncurrentAssets |
| Inventories | ₹2.79 Bn | ₹3.50 Bn | ₹3.86 Bn | ₹5.10 Bn | Inventories |
| Trade Receivables | ₹3.62 Bn | ₹3.74 Bn | ₹3.16 Bn | ₹5.41 Bn | TradeReceivablesCurrent |
| Cash and Cash Equivalents | ₹0.45 Bn | ₹0.88 Bn | ₹1.32 Bn | ₹0.77 Bn | CashAndCashEquivalents |
| Current Investments | ₹0.00 Bn | ₹0.00 Bn | ₹1.08 Bn | ₹0.00 Bn | CurrentInvestments |
| Other Current Assets | ₹0.54 Bn | ₹0.77 Bn | ₹0.69 Bn | ₹0.72 Bn | OtherCurrentAssets |
| Total Current Assets | ₹7.61 Bn | ₹9.21 Bn | ₹11.39 Bn | ₹14.83 Bn | CurrentAssets |
| Total Assets | ₹15.80 Bn | ₹18.33 Bn | ₹21.80 Bn | ₹29.30 Bn | Assets |
| Equity Share Capital | ₹0.13 Bn | ₹0.13 Bn | ₹0.13 Bn | ₹0.13 Bn | EquityShareCapital |
| Other Equity | ₹9.81 Bn | ₹12.70 Bn | ₹15.12 Bn | ₹18.62 Bn | OtherEquity |
| Equity Attributable to Owners | ₹9.94 Bn | ₹12.83 Bn | ₹15.25 Bn | ₹18.74 Bn | EquityAttributableToOwnersOfParent |
| Non-controlling Interests | N/A | ₹0.00 Bn | ₹0.00 Bn | ₹0.00 Bn | NonControllingInterest |
| Total Equity | ₹9.94 Bn | ₹12.83 Bn | ₹15.25 Bn | ₹18.74 Bn | Equity |
| Long-term Borrowings | ₹0.74 Bn | ₹0.45 Bn | ₹0.91 Bn | ₹1.61 Bn | BorrowingsNoncurrent |
| Total Non-current Liabilities | ₹1.47 Bn | ₹1.22 Bn | ₹1.89 Bn | ₹3.45 Bn | NoncurrentLiabilities |
| Short-term Borrowings | ₹0.47 Bn | ₹0.38 Bn | ₹0.45 Bn | ₹0.36 Bn | BorrowingsCurrent |
| Trade Payables | ₹1.71 Bn | ₹1.92 Bn | ₹2.52 Bn | ₹2.69 Bn | TradePayablesCurrent |
| Other Current Liabilities | ₹1.40 Bn | ₹0.86 Bn | ₹0.79 Bn | ₹2.53 Bn | OtherCurrentLiabilities |
| Total Current Liabilities | ₹4.39 Bn | ₹4.28 Bn | ₹4.66 Bn | ₹7.10 Bn | CurrentLiabilities |
| Total Equity and Liabilities | ₹15.80 Bn | ₹18.33 Bn | ₹21.80 Bn | ₹29.30 Bn | EquityAndLiabilities |
Every figure above is the exact value of the named XBRL element from NEULANDLAB.NS's cached filing for that year — nothing here is estimated or backfilled. A company shows one column per year StockProof actually has data for — never padded with blank years. Rows shown as N/A are genuinely not disclosed under that year's filing format (see peer comparison for how other Healthcare companies compare).